Data Moats: Defending ECG AI from Tech Giants

Investors in digital health want one thing: defensible market positions. Everyone talks about AI, but few on the outside get what actually creates a competitive advantage that lasts. For a late-stage VC or a public market analyst, figuring out how a company uses its proprietary clinical data to build an impenetrable data moat isn’t an academic exercise, it’s the core of how you value the business.

Here, we’ll look at how specialized data stops big tech from just waltzing into the clinical arrhythmia monitoring space. Companies like iRhythm Technologies and AliveCor are perfect examples of vertical AI healthcare companies that have built walls around their businesses, and their strategy gives us a solid model for judging data defensibility when looking at any digital health investment.

The Irreplicable Edge: Why Generalist AI Cannot Match Specialized ECG Algorithms

There’s a persistent idea that a big tech company could just point its massive general-purpose AI at a problem and solve it, but that thinking completely falls apart in a field like automated arrhythmia detection. The real bottleneck isn’t computing power. It’s getting the huge, diverse, and expertly annotated disease-specific datasets you need to train and then validate a diagnostic algorithm that actually works and can get past regulators.

Cardiac electrophysiology is a uniquely hard problem for AI. Arrhythmias are incredibly varied, sometimes subtle, and often look different from patient to patient. To spot these patterns correctly, an algorithm needs training on a massive library of clean, clinically validated ECGs that have been annotated by board-certified cardiologists and electrophysiologists. You have to curate a dataset that captures everything from rare pathologies and signal artifacts to the borderline cases that fool less sophisticated models. A generalist AI without this deep, specific data would be plagued by algorithmic drift and could never get the kind of diagnostic accuracy needed for SaMD (Software as a Medical Device) clearance.

“Without a PCCP, every time your cardiac AI model retrains on new data, you need a new 510(k), that’s unscalable.”

Building the Moat: Dataset Scale and Clinical Validation as Competitive Barriers

The competitive edge that disease-specific AI health platforms like iRhythm and AliveCor have comes straight from their proprietary ECG datasets. These collections of data are clinically rich, have been labeled by experts, and are always growing, which creates the data moat that makes it so hard for anyone else to compete.

iRhythm Technologies: The Zio Patch and Unrivaled Data Depth

iRhythm is a leader in long-term ambulatory cardiac monitoring because of its Zio XT and Zio AT patches, but its real success is tied to the mountain of ECG data it has collected. Think about it: their latest investor reports show they’ve processed over 10 million patient reports. That’s more than 2 billion hours of curated ECG data. iRhythm Technologies investor relations, most recent annual report

This dataset isn’t just a pile of raw signals, it’s the result of years of clinical work where every single recording gets reviewed and annotated by an expert. That human-in-the-loop process creates the “ground truth” that’s absolutely required to train and retrain their arrhythmia detection algorithms. With that much high-quality labeled data, iRhythm’s algorithms can hit high sensitivity and specificity on everything from atrial fibrillation to much rarer arrhythmias. Their clinical validation is all over peer-reviewed journals, which builds their authority and backs up their stack of FDA 510(k) clearances. Heart Rhythm Society journal publications citing iRhythm Zio data

AliveCor: KardiaMobile and Accessible Diagnostic Power

AliveCor’s model for data defensibility is different but just as strong, built on its patient-facing KardiaMobile devices. They focus on on-demand ECGs that patients take themselves. The recordings are shorter than iRhythm’s, but AliveCor makes up for it in volume from millions of users worldwide, having analyzed over 350 million ECGs according to their own materials. That volume gives them an incredibly diverse dataset. AliveCor investor presentations, publicly available data

Just like iRhythm, AliveCor trains its algorithms on its proprietary data, which lets them detect common problems like atrial fibrillation with high accuracy. The fact that they can give FDA-cleared, useful insights straight to patients and doctors proves how valuable that specialized data is. Every time they collect more data, refine the algorithm, and get more clinical validation through their partnerships, their data moat gets deeper. It’s a feedback loop that has let them secure a whole series of 510(k) clearances for different arrhythmia detections.

Evaluating Data Defensibility: A Model for Investors

If you’re a late-stage VC or a public market analyst, you have to know how to evaluate the defensibility of a digital health company’s dataset. This is how you get past the surface-level metrics and find the real competitive advantage. Here’s a framework for doing it:

1. Scale and Diversity of Labeled Data: You need the raw numbers for volume (hours of ECG, number of patients) but also the diversity. Ask the hard questions. Does the dataset represent a wide range of demographics, comorbidities, and arrhythmia types? Is it just from clean clinical trials, or is it messy, valuable Real-World Evidence (RWE)?
2. Quality of Annotation and Ground Truth: Dig into how the data is labeled. Is it a rigorous process run by experts? Who are these annotators (e.g., board-certified electrophysiologists)? The quality of this ground truth is everything, it dictates both algorithm performance and whether the FDA will ever sign off on it.
3. Proprietary Nature and Exclusivity: Is this data actually proprietary? Or could a competitor just buy it or scrape it from public sources? Companies that generate their own data through their own devices and services, like iRhythm and AliveCor, have a much stronger data moat.
4. Regulatory Validation and Clinical Evidence: Has the algorithm actually been cleared by the FDA via a 510(k) or De Novo classification? Are there peer-reviewed papers proving it works in the real world? Without this, you have no commercial product and no path to reimbursement. It’s a deal-breaker.
5. Continuous Data Ingestion and Model Improvement: What’s the plan for the future? Is there a built-in way for the company to keep collecting new data and feeding it back into the model? This is the only way to fight algorithmic drift and stay ahead. Seeing a PCCP on the roadmap is a very good sign they’re thinking ahead.
6. Data Security and Privacy Compliance: With sensitive health data, having your ducks in a row on HIPAA, HITRUST, and SOC 2 is table stakes. It’s a regulatory checkbox, but it’s also how you build the trust you need with both patients and hospital systems.

The Case for Vertical Specialization in AI Health

The stories of iRhythm and AliveCor prove a simple point: vertical AI healthcare companies that go deep on one disease have a huge advantage over generalist platforms. This advantage is built on their proprietary, disease-specific datasets, which are curated and used in a way that’s impossible for a big tech company to copy. They can’t replicate the clinical depth or the expert annotation.

A big tech firm has plenty of computing power, but it doesn’t have the years of clinical experience, the patient relationships, or the regulatory know-how these specialists have. Getting from a raw ECG signal to an FDA-cleared product is a long road that requires cardiologists, regulatory experts, and a real understanding of how patients move through the healthcare system. It’s that whole team, focused on one clinical problem, that creates the strong data moat.

So for investors, the takeaway is to back companies with a clear, proven strategy for getting and validating their own proprietary data. Those are the companies that get through the FDA, secure reimbursement with things like CPT codes, and actually create lasting value. The defensible moat built from proprietary ECG data is maybe the best example out there of why going deep and narrow as a vertical specialist is the winning strategy in AI health.